[In vivo CAR-Ts, a significant breakthrough].

Since 2017, the CAR-T ex vivo approach has been very successful for the treatment of B cell malignancies in spite of its complexity and cost. A novel method involves transforming T lymphocytes into CAR-T cells in situ (therefore, in vivo) and promises simplicity, speed and affordability. It also seems applicable to several autoimmune diseases and is currently the object of much activity and interest in academic and corporate environments.